Efficacy and safety of IVIG in CIDP : Combined data of the PRIMA and PATH studies

Show full item record




PRIMA Trial Investigators PATH , Merkies , I S J , van Schaik , I N , Leger , J-M , Saarela , M & Mielke , O 2019 , ' Efficacy and safety of IVIG in CIDP : Combined data of the PRIMA and PATH studies ' , Journal of the Peripheral Nervous System , vol. 24 , no. 1 , pp. 48-55 . https://doi.org/10.1111/jns.12302

Title: Efficacy and safety of IVIG in CIDP : Combined data of the PRIMA and PATH studies
Author: PRIMA Trial Investigators PATH; Merkies, Ingemar S. J.; van Schaik, Ivo N.; Leger, Jean-Marc; Saarela, Mika; Mielke, Orell
Contributor organization: Neurologian yksikkö
Department of Food and Nutrition
HUS Neurocenter
Date: 2019-03
Language: eng
Number of pages: 8
Belongs to series: Journal of the Peripheral Nervous System
ISSN: 1085-9489
DOI: https://doi.org/10.1111/jns.12302
URI: http://hdl.handle.net/10138/300710
Abstract: Intravenous immunoglobulin (IVIG) is a potential therapy for chronic inflammatory demyelinating polyneuropathy (CIDP). To investigate the efficacy and safety of the IVIG IgPro10 (Privigen) for treatment of CIDP, results from Privigen Impact on Mobility and Autonomy (PRIMA), a prospective, open-label, single-arm study of IVIG in immunoglobulin (Ig)-naive or IVIG pre-treated subjects (NCT01184846, n = 28) and Polyneuropathy And Treatment with Hizentra (PATH), a double-blind, randomized study including an open-label, single-arm IVIG phase in IVIG pre-treated subjects (NCT01545076, IVIG restabilization phase n = 207) were analyzed separately and together (n = 235). Efficacy assessments included change in adjusted inflammatory neuropathy cause and treatment (INCAT) score, grip strength and Medical Research Council (MRC) sum score. Adverse drug reactions (ADRs) and ADRs/infusion were recorded. Adjusted INCAT response rate was 60.7% in all PRIMA subjects at Week 25 (76.9% in IVIG pre-treated subjects) and 72.9% in PATH. In the pooled cohort (n = 235), INCAT response rate was 71.5%; median time to INCAT improvement was 4.3 weeks. No clear demographic differences were noticed between early (responding before Week 7, n = 148) and late responders (n = 21). In the pooled cohort, median change from baseline to last observation was -1.0 (interquartile range -2.0; 0.0) point for INCAT score; +8.0 (0.0; 20.0) kPa for maximum grip strength; +3.0 (1.0; 7.0) points for MRC sum score. In the pooled cohort, 271 ADRs were reported in 105 subjects (44.7%), a rate of 0.144 ADRs per infusion. This analysis confirms the efficacy and safety of IgPro10, a recently FDA-approved IVIG for CIDP, in a population of mainly pre-treated subjects with CIDP [Correction added on 14 March 2019 after first online publication: the INCAT response rate has been corrected.].
Subject: CIDP
3112 Neurosciences
3124 Neurology and psychiatry
Peer reviewed: Yes
Rights: cc_by
Usage restriction: openAccess
Self-archived version: publishedVersion

Files in this item

Total number of downloads: Loading...

Files Size Format View
Merkies_et_al_2 ... ipheral_Nervous_System.pdf 549.8Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record